Bharat Immunologicals & Biologicals Corporation Limited reported earnings results for the full year ended March 31, 2023. For the full year, the company reported sales was INR 446.09 million compared to INR 783.88 million a year ago. Revenue was INR 474.12 million compared to INR 794.9 million a year ago.

Net loss was INR 170.57 million compared to INR 87.54 million a year ago. Basic loss per share from continuing operations was INR 3.95 compared to INR 2.03 a year ago. Diluted loss per share from continuing operations was INR 3.95 compared to INR 2.03 a year ago.